Ekso Bionics Announces Research Partnership with Shepherd Center
25 Giugno 2024 - 2:00PM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or
“Ekso”), an industry leader in exoskeleton technology for medical
and industrial use, today announced a research partnership with
Shepherd Center, a renowned rehabilitation hospital in Atlanta, to
incorporate EksoNR and Ekso Indego devices across its
rehabilitation and community network. Shepherd Center provides
world-class clinical care, research, and family support for people
experiencing the most complex conditions, including spinal cord and
brain injuries, multi-trauma, traumatic amputations, stroke,
multiple sclerosis, and pain.
As part of the partnership, Ekso and Shepherd
Center will work collaboratively to design a research and training
program for the Ekso devices. The experience is expected to
contribute to the evolving understanding of best practices for
implementing Ekso training into a clinical program, as well as for
individual use of the Ekso Indego Personal device.
Shepherd Center will also work with Ekso to
design a training program for the Ekso Indego Personal device,
which Ekso expects will offer individuals the opportunity to
experience and explore exoskeleton technology, empowering those
interested in purchasing a home device with the knowledge and
skills needed for successful integration into their daily lives.
Shepherd Center’s spinal cord injury (SCI) expertise and
programming is uniquely positioned to investigate the clinical and
quality of life benefits associated with incorporating exoskeleton
technology throughout the continuum of care from hospital to
home.
“We are thrilled to partner with Shepherd Center
to advance the integration of our unique exoskeleton technology in
the rehabilitation and community settings,” said Scott Davis, Chief
Executive Officer of Ekso Bionics. “This collaboration comes at a
pivotal moment, following the recent decision by the Centers for
Medicare & Medicaid Services to provide a reimbursement rate
for Ekso Indego Personal, opening new avenues for accessibility and
patient care to individuals living with SCI. Our research
partnership with Shepherd aligns with our mission to empower
individuals with mobility challenges and enhance their overall
quality of life.”
“Shepherd Center is proud to be at the forefront
of innovation in rehabilitation,” said Deborah Backus, PT, Ph.D.,
FACRM, Vice President of Research and Innovation at Shepherd
Center. “We expect that incorporating Ekso’s exoskeleton
devices into our rehab center will not only benefit our patients
across the continuum of care, but also contribute valuable insights
to the broader medical community.”
About Ekso
Bionics®
Ekso Bionics® is a leading developer of
exoskeleton solutions that amplify human potential by supporting or
enhancing strength, endurance and mobility across medical and
industrial applications. Founded in 2005, the Company continues to
build upon its industry-leading expertise to design some of the
most cutting-edge, innovative wearable robots available on the
market. Ekso Bionics is the only known exoskeleton company to offer
technologies that range from helping those with paralysis to stand
up and walk, to enhancing human capabilities on job sites across
the globe. The Company is headquartered in the San Francisco Bay
Area and is listed on the Nasdaq Capital Market under the symbol
“EKSO.” For more information, visit: www.eksobionics.com or follow
@EksoBionics on X.
About Shepherd Center
Shepherd Center provides world-class clinical
care, research, and family support for people experiencing the most
complex conditions, including spinal cord and brain injuries,
multi-trauma, traumatic amputations, stroke, multiple sclerosis,
and pain. An elite center recognized as both Spinal Cord
Injury and Traumatic Brain Injury Model Systems, Shepherd Center is
ranked by U.S. News as one of the nation’s top hospitals for
rehabilitation. Shepherd Center treats thousands of patients
annually with expertise and compassion to help them begin
again.
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements. Forward-looking statements may include,
without limitation, statements regarding (i) the potential benefits
of EksoNR or Ekso Indego, (ii) the performance or effectiveness of
the Company’s products, including the EksoNR or Ekso Indego, (iii)
the details of and expected results from the Company’s research
collaboration with Shepherd Center, including the expected benefits
to patients and potential promotion of the Company’s devices, and
(iv) the assumptions underlying or relating to any statement
described in clauses (i), (ii) and (iii) above. Such
forward-looking statements are not meant to predict or guarantee
actual results, performance, events or circumstances and may not be
realized because they are based upon the Company’s current
projections, plans, objectives, beliefs, expectations, estimates
and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, patient or therapist dissatisfaction
with EksoNR, any delay or discontinuation of the research
collaboration, or Ekso Indego and risks related to product
liability, recall and warranty claims. These and other factors are
identified and described in more detail in the Company’s filings
with the U.S. Securities and Exchange Commission. To learn more
about Ekso Bionics please visit the Company’s website at
www.eksobionics.com or follow @EksoBionics on X. The Company does
not undertake to update these forward-looking statements.
Contacts: Investors:David
CareyFINN Partners212-867-1768investors@eksobionics.com
Grafico Azioni Ekso Bionics (NASDAQ:EKSO)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Ekso Bionics (NASDAQ:EKSO)
Storico
Da Nov 2023 a Nov 2024